
|Videos|October 20, 2017
Dr. Zhang Discusses the Impact of the STAMPEDE Trial in Prostate Cancer
Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the impact of the STAMPEDE trial in prostate cancer.
Advertisement
Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the impact of the STAMPEDE trial in prostate cancer.
The STAMPEDE trial compared abiraterone acetate (Zytiga) to androgen deprivation therapy (ADT) in patients with metastatic and nonmetastatic prostate cancer.
Early disease-free survival benefits are being seen with abiraterone acetate in the nonmetastatic setting, suggesting it could be a marker for overall survival benefit, says Zhang.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Hematology Experts Preview Key Abstracts to Watch at the 2026 Transplantation & Cellular Therapy Meetings
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
Latest ACS Cancer Statistics Report Outlines Notable Gains, Remaining Gaps Across Tumor Types
5



































